Promakhos Therapeutics is focused on developing innovative therapies aimed at restoring the balance and function of the immune system to effectively treat autoinflammatory diseases. Unlike traditional therapies that primarily suppress the immune response and address symptoms, Promakhos seeks to tackle the root causes of chronic inflammation associated with conditions such as Crohn’s disease, multiple sclerosis, and ankylosing spondylitis. The company’s approach is rooted in the belief that by enhancing the body’s natural ability to control inflammation, patients can achieve better long-term outcomes. This transformative strategy is designed to empower the immune system rather than work against it, potentially benefiting a larger percentage of patients who currently do not respond well to existing treatments.

The team at Promakhos Therapeutics comprises experienced scientists and entrepreneurs with diverse backgrounds in immunology, microbiology, and drug discovery. Their collective expertise includes pioneering work in areas such as CRISPR technology for genetic engineering, the role of the microbiome in health, and the development of immunomodulatory drugs. The company is committed to translating scientific research into practical therapies that can improve patient outcomes, leveraging insights from both academic and clinical settings. By focusing on the interplay between the immune system and inflammation, Promakhos aims to create novel therapeutic solutions that address the complexities of chronic inflammatory diseases.

United States

Promakhos Therapeutics is an Allston-based biotech startup founded in the spring of 2021. The company aims to develop curative therapies that restore the body's innate ability to fight inflammatory disorders. Promakhos Therapeutics focuses on creating therapies for autoinflammatory diseases based on a new and unexplored mechanism.

Promakhos Therapeutics

Company Details